浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Clinical advantages of nebivolol in the treatment of hypertension
- ZHONGGUO YAOFANG Vol. 34, Issue 16, Pages: 2044-2048(2023)
- 作者机构：
1.青岛市妇女儿童医院临床药学科，山东 青岛 266034
2.中国人民解放军92038部队卫生队，山东 青岛 266200
3.中国人民解放军海军第九七一医院药剂科，山东 青岛 266071
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.16.24
CLC： R969.3;R972+.4Published：30 August 2023，
Received：30 November 2022，
Revised：25 June 2023，
扫 描 看 全 文
李萍,刘畅,谷晓策等.奈必洛尔用于高血压的临床治疗优势 Δ[J].中国药房,2023,34(16):2044-2048.
LI Ping,LIU Chang,GU Xiaoce,et al.Clinical advantages of nebivolol in the treatment of hypertension[J].ZHONGGUO YAOFANG,2023,34(16):2044-2048.
李萍,刘畅,谷晓策等.奈必洛尔用于高血压的临床治疗优势 Δ[J].中国药房,2023,34(16):2044-2048. DOI： 10.6039/j.issn.1001-0408.2023.16.24.
LI Ping,LIU Chang,GU Xiaoce,et al.Clinical advantages of nebivolol in the treatment of hypertension[J].ZHONGGUO YAOFANG,2023,34(16):2044-2048. DOI： 10.6039/j.issn.1001-0408.2023.16.24.
摘要
β受体阻滞剂是常用的抗高血压药之一，该类药物对β受体的选择性存在明显差异。奈必洛尔为第三代β受体阻滞剂，作用机制独特。本文通过对奈必洛尔近年在降压方面的临床应用进行归纳总结发现，与其他β受体阻滞剂相比，奈必洛尔具有一定的临床治疗优势，除降压效果明显外，还对患者性功能、心率影响较小，且不影响血糖、血脂代谢等，因此该药更适用于一些特殊群体患者，包括性活跃的男性高血压患者及合并有2型糖尿病、代谢综合征等并发症的高血压患者。
Abstract
β-blocker is one of the commonly used anti-hypertensive drugs， and there are obvious differences in the selection of this class of drugs. Nebivolol is a third-generation β-blocker with a unique mechanism of action. This article summarizes the clinical application of nebivolol in anti-hypertensive treatment in recent years， and it is found that compared with other β-blockers， nebivolol has certain clinical treatment advantages. In addition to having a significant antihypertensive effect， it also has little impact on sexual function and heart rate of patients， and does not affect the blood glucose and lipid metabolism， so the drug is more suitable for some special groups of patients， including sexually active male hypertensive patients， hypertensive patients with complications such as type 2 diabetes mellitus and metabolic syndrome.
关键词
奈必洛尔β受体阻滞剂抗高血压临床优势
Keywords
β-blockeranti-hypertensiveclinical advantages
references
WILLIAMS B，MANCIA G，SPIERING W，et al. 2018 ESC/ESH guidelines for the management of arterial hypertension[J].Eur Heart J，2018，39（33）：3021-3104.
FONGEMIE J，FELIX-GETZIK E. A review of nebivolol pharmacology and clinical evidence[J]. Drugs，2015，75（12）：1349-1371.
CHO K I，JEON D W，AHN H S，et al. Efficacy and safety of nebivolol in Korean patients with hypertension by age and sex：a subanalysis from the BENEFIT-KOREA study[J]. Clin Hypertens，2021，27（1）：9.
ALTIN C，OKYAY K，KIS M. et al. The safety and tole- rability of nebivolol in hypertensive patients with coronary artery disease and left ventricular ejection fraction≥40%：a population-based cohort study[J].Turk Kardiyol Dern Ars，2022，50（8）：568-575.
ZHAO Y Z，VANHOUTTE P M，LEUNG S W. Vascular nitric oxide：beyond eNOS[J]. J Pharmacol Sci，2015，129（2）：83-94.
NAPOLI C，PAOLISSO G，CASAMASSIMI A，et al. Effects of nitric oxide on cell proliferation：novel insights[J]. J Am Coll Cardiol，2013，62（2）：89-95.
SHARP R P，GALES B J. Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction[J]. Ther Adv Urol，2017，9（2）：59-63.
DUPREZ D A，FLOREA N，DUVAL S，et al. Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure：the EVIDENCE study[J]. J Hum Hypertens，2017，32（1）：20-25.
DIEHL K J，STAUFFER B L，DOW C A，et al. Chronic nebivolol treatment suppresses endothelin-1-mediated vasoconstrictor tone in adults with elevated blood pressure[J]. Hypertension，2016，67（6）：1196-1204.
COATS A，JAIN S. Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage[J]. J Hum Hypertens，2017，31（6）：376-381.
SELEME V B，MARQUES G L，MENDES A E M，et al. Nebivolol for the treatment of essential systemic arterial hypertension：a systematic review and meta-analysis[J]. Am J Cardiovasc Drugs，2021，21（2）：165-180.
LIU J Y，GUO L N，PENG W Z，et al. Efficacy and safety of nebivolol in hypertensive patients：a meta-analysis of randomized controlled trials[J]. J Int Med Res，2020，48（10）：300060520931625.
VAZ-DE-MELO R O，GIOLLO-JÚNIOR L T，MARTINELLI D D，et al. Nebivolol reduces central blood pressure in stage Ⅰ hypertensive patients：experimental single cohort study[J]. Sao Paulo Med J，2014，132（5）：290-296.
BORGHI C，ACELAJADO M C，GUPTA Y，et al. Role of nebivolol in the control and management of central aortic blood pressure in hypertensive patients[J]. J Hum Hypertens，2017，31（10）：605-610.
SOANKER R，NAIDU M U，RAJU S B，et al. Effect of beta-1-blocker，nebivolol，on central aortic pressure and arterial stiffness in patients with essential hypertension[J]. Indian J Pharmacol，2012，44（3）：407-411.
BASILE J，EGAN B，PUNZI H，et al. Risk of hospitalization for cardiovascular events with β-blockers in hypertensive patients：a retrospective cohort study[J]. Cardiol Ther，2018，7（2）：173-183.
HUCK D M，ROSENBERG M A，STAUFFER B L. Nebivolol and incident cardiovascular events in hypertensive patients compared with nonvasodilatory beta blockers[J]. J Hypertens，2022，40（5）：1019-1029.
MANOLIS A，DOUMAS M，FERRI C，et al.Erectile dysfunction and adherence to antihypertensive therapy-focus on β-blockers[J]. Eur J Intern Med，2020，81：1-6.
BRIXIUS K，MIDDEKE M，LICHTENTHAL A，et al. Nitric oxide，erectile dysfunction and beta-blocker treatment （MR NOED study）：benefit of nebivolol versus metoprolol in hypertensive men[J]. Clin Exp Pharmacol Physiol，2007，34（4）：327-331.
ALDEMIR M，KELEŞ İ，KARALAR M，et al. Nebivolol compared with metoprolol for erectile function in males undergoing coronary artery bypass graft[J]. Anatol J Cardiol，2016，16（2）：131-136.
GÜR Ö，GURKAN S，YUMUN G，et al. The comparison of the effects of nebivolol and metoprolol on erectile dysfunction in the cases with coronary artery bypass surgery[J]. Ann Thorac Cardiovasc Surg，2017，23（2）：91-95.
GUNGOR G，PERK H，SOYUPEK S，et al. Nebivolol protects erectile functions compared to metoprolol in hypertensive men with atherogenic，venogenic，psychogenic erectile dysfunction：a prospective，randomized，cross-over，clinical trial[J]. Eur J Intern Med，2022，103：69-75.
NASIMA O，MARCUS K，DANIELA G，et al.Nebivolol in the treatment of arterial hypertension[J].Basic Clin Pharmacol Toxicol，2019，125（3）：189-201.
MARKETOU M，GUPTA Y，JAIN S，et al. Differential metabolic effects of beta-blockers：an updated systematic review of nebivolol[J]. Curr Hypertens Rep，2017，19（3）：22.
LADAGE D，REIDENBACH C，RIECKEHEER E，et al. Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age[J]. J Cardiovasc Pharmacol，2010，56（3）：275-281.
METWALLY Y G，SEDRAK H K，SHALTOUT I F. Effect of carvedilol versus nebivolol on insulin resistance among non-diabetic，non-ischemic cardiomyopathy with heart failure[J]. Egypt Heart J，2020，72（1）：63.
OZYILDIZ A G，EROGLU S，BAL U，et al. Effects of carvedilol compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension[J]. J Cardiovasc Pharmacol Ther，2017，22（1）：65-70.
朱海，王志禄，元朝波，等. 奈必洛尔与第2代β受体阻断药治疗高血压的有效性及安全性的Meta分析[J]. 医药导报，2016，35（8）：886-892.
WEHLAND M，GROSSE J，SIMONSEN U，et al. The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease[J]. Curr Vasc Pharmacol，2012，10（3）：378-390.
BHOSALE V V，INAMDAR S C，V B K，et al. Beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension[J]. J Clin Diagn Res，2014，8（6）：HC01-HC04.
VELASCO A，SOLOW E，PRICE A，et al. Differential effects of nebivolol vs. metoprolol on microvascular function in hypertensive humans[J]. Am J Physiol Heart Circ Physiol，2016，311（1）：H118-H124.
STAUFFER B L，DOW C A，DIEHL K J，et al. Nebivolol，but not metoprolol，treatment improves endothelial fibri- nolytic capacity in adults with elevated blood pressure[J]. J Am Heart Assoc，2017，6（11）：e007437.
MOMI S，CARACCHINI R，FALCINELLI E，et al. Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis[J]. Arterioscler Thromb Vasc Biol，2014，34（4）：820-829.
KOZLOVSKI V I，LOMNICKA M，BARTUS M，et al. Anti-thrombotic effects of nebivolol and carvedilol：involvement of β2 receptors and COX-2/PGI2 pathways[J]. Pharmacol Rep，2015，67（5）：1041-1047.
0
Views
15
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.